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Abstract : The incidence of proximal extension in patients with ulcerative proc-
titis is reported to be 18%-46%, but recent data on the incidence in Japan is 
inadequate.  The aim of this study was to investigate the incidence of proximal 
extension of ulcerative proctitis and factors associated with the extension in 
Japan.  This is a retrospective observational study involving a cohort of 53 
patients with an initial diagnosis of ulcerative proctitis.  Following verication 
of the diagnoses, demographic and clinical data were compiled.  The cumula-
tive incidence of proximal extension was estimated as ‘person-years’ and cumu-
lative probability was calculated by the Kaplan-Meyer method.  Univariate and 
multivariate analyses were performed to identify association factors.  During a 
mean follow-up of 6.8 years, proximal extension was observed in 14 patients 
（26.4%）.  The cumulative incidence of proximal extension was 4.22/100 person-
years and the cumulative probability at 5 years was 20.1%, consistent with 
recent reports from Western countries and data obtained in Japan over 2 
decades ago.  Univariate analysis showed active smoking （P = 0.025） and 
corticosteroid therapy （P = 0.006） to be risk factors in proximal extension, 
however multivariate analysis revealed that corticosteroid therapy was the only 
signicant factor （P = 0.005） separating patients with and without proximal 
extension.  No patient underwent colectomy.  The incidence of proximal exten-
sion in ulcerative proctitis in Japan is comparable to that in Western countries 
and has not changed signicantly over the past two decades.  Corticosteroid 
therapy was identied as the only signicant factor in proximal extension.
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Introduction
　Ulcerative colitis （UC） is a chronic relapsing-remitting inammatory bowel disease （IBD） 
with symptoms which impair performance and quality of life.  One feature of UC is that 
the inammation diffusely and continuously extends from the distal to the proximal colon 
and that the rectum is primarily involved, which is a hallmark of this disease 1）.
　Among patients with UC, proctitis has the following distinct characteristics compared to 
those of left-sided or extensive disease: high age of onset, minimal cancer risk, and a low 
frequency of the most common complications such as toxic megacolon and bleeding 2, 3）. 
Although the clinical impact of ulcerative proctitis is not very signicant, it accounts for 
one-third of all UC patients 4） and the occurrence of proctitis in UC has steadily increased 
in the past few decades 3, 5）.  In addition, it has been reported that the rate of colectomy 
increases once the proctitis is entirely extended 3, 6）.
　To make prudent therapeutic decisions in patients with active UC, it is essential to assess 
both the extent of anatomical involvement as well as the severity of inammation.  Thus 
the extent of UC has been recognized as one prognostic factor ; extensive disease increases 
the risk of complications like bleeding and megacolon, which can lead to surgical interven-
tion 3, 7）.  Similarly, UC is a life-long disorder with an unpredictable disease course, which is 
an additional source of concern for patients 8）.  Accordingly, knowledge of the natural course 
of the disease, particularly, changes in the progression of the disease over time are valuable. 
We reviewed the literature on the natural history of UC and the profile of inflamma-
tion, and found considerable heterogeneity ; the incidence of proximal extension has been 
reported to be 20%-50% , while regression has also been observed9, 10）.
　The natural history of ulcerative proctitis has been investigated mostly in Western 
countries and, as mentioned above, disease extension is estimated to be 18%-46% 9-15）. 
However, factors previously identied as contributing to disease extension have been chal-
lenged 3, 6, 10, 11）.  In addition, there have been very few reports describing the natural course 
of ulcerative proctitis in Japan.  Hiwatashi et al 14） reported that 21 of 76 ulcerative proctitis 
patients experienced disease extension, with half of those patients developing the extension 
within 3 years of onset, bearing in mind that the patients in the study were recruited from 
1954 to 1987.  In addition, the prevalence of UC has steadily increased during the past two 
decades 16）; the current incidence of UC in Japan is estimated to be more than 4 times the 
level when Hiwatashi and colleagues carried out their study 14）.  Therefore, it is important to 
know if the natural course of this disorder has changed since 1987.  Hence, the objective in 
this study was to investigate the current incidence of disease extension in ulcerative proctitis 
in Japan, and examine factors associated with this disease extension.
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Materials and Methods
Patients and study design
　This was a retrospective observational investigation conducted at three tertiary care institu-
tions in Japan.  The study population comprised a cohort of 53 patients with a previous 
diagnosis of ulcerative proctitis between 1997 and 2008.  The patients were followed-up for 
at least 3 years by a second colonoscopy.  The colonoscopy was performed on the basis of 
clinical needs and not regularly scheduled.  The end of the observation period in patients 
without disease extension was the nal clinical or endoscopic follow-up.  Observations ceased 
when disease extension was documented.
Diagnosis of ulcerative proctitis
　Diagnosis of ulcerative proctitis was based on the following 4 criteria.  1） Patients had 
experienced chronic diarrhea, bloody stool, or pus in the stool.  2） Colonoscopy revealed at 
least one macroscopic nding, including absence of vascular patterns, friability, granularity or 
erosions, which was conned to the rectosigmoid junction.  The severity of the endoscopic 
ndings was determined according to Matt’s score 17）.  3） Histopathological ndings demon-
strated diffuse inltration of inammatory cells, and presence of either cryptitis or a crypt 
abscess.  Depletion of goblet cells, distortion of glands, and basal plasmacytosis were not 
essential.  We did not determine the histological severity because of the lack of a validated 
scoring system.  4） Infectious disease was ruled out.  The diagnoses of all cases were veri-
ed retrospectively by review of colonoscopy photographs and medical records.
Denition of proximal extension
　Denition of proximal extension was the presence of macroscopic inammation extending 
beyond the rectosigmoid junction judged by any follow-up colonoscopy.  Time to proximal 
extension was defined as the period between the onset of symptoms and the time of 
colonoscopy when the extension was documented.
Demographic data
　Demographic data included age at onset, gender, family history, smoking habits, corti-
costeroid therapy, clinical course, appendiceal involvement, and the use of aminosalicylates 
（mesalamine or sulphasalazine）.  Family history was dened as positive if there was any 
UC or Crohn’s disease in a relative irrespective of family closeness （parent, child, sibling, 
grandparent, aunt, uncle, or cousin）.  Patients were dened as active smokers if they were 
regularly smoking at the time of diagnosis of proximal extension.  The number of cigarettes 
and how long they had been smoking did not matter.  Doses of mesalamine or sulphasala-
zine used for treatment were mostly 2.25 g or 3 g, respectively.  Corticosteroid was given 
orally or topically ; 0.6 mg/kg of oral predonisolone or 1 mg of betamethasone.  The clinical 
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course was classified as one attack, flare up-remission, or chronic active.  Definition of 
chronic active was symptoms continuing for more than 6 months.
Statistical analysis
　Continuous values are expressed as median or mean values with ranges, while categorical 
data are expressed as frequency and percentages.  Cumulative rates of proximal extension 
were calculated by the Kaplan-Meier method and cumulative incidence was estimated to be 
100 ‘person-years.’ For comparison between patients with and without disease extension, the 
chi-square test or Fisher exact test was applied, while the Mann-Whitney U test was applied 
for descriptive and numerical data.  To determine an associated factor for disease extension, 
univariate analysis for individual factors was applied and the signicance level was based 
on the signed log-rank test.  For this analysis, age at onset was converted to dichotomous 
by splitting with the median, and the three categories of clinical course were also converted 
to a dichotomous variable ; are up-remission and chronic active were categorized as active 
disease.  Factors signicant in the univariate analysis were used in the Cox proportional haz-
ards model with a stepwise procedure to adjust for potential confounders.  For all analyses, 
a two-tailed P-value ＜ 0.05 was considered statistically signicant.  The software used for 
statistical analyses was SPSS for Windows.
Ethical Considerations
　The protocol of this investigation was reviewed and approved by the Ethics Committees 
at all three participating institutions.
Results
Clinical outcomes
　Among the 53 patients in the study, 15 were males and 38 were females.  The median 
age at onset was 33 years, range 18 to 73 years （Table 1）.  Positive family history and 
active smoking was present in 3 （5%） and 7 patients （13%）, respectively.  At the time of 
the rst diagnosis, 21 patients （40%） presented with appendiceal involvement.  During the 
clinical course of the disease, 28 patients （53%） experienced are-ups and 9 patients （17%） 
presented with chronic active disease.  One patient did not receive any medication in the 
follow-up period, but all other patients were taking either mesalamine or sulphasalazine. 
Corticosteroid was taken was by 17 patients （32%）.  The mean follow-up time was 6.8 
years, ranging from 3 to 20 years.  No patient underwent colectomy during the follow-up 
period.  Only corticosteroid therapy was signicantly different between patients with and 
without proximal extension （P = 0.005）.  The significance levels for active smoking and 
clinical course were P = 0.06 and P = 0.07, respectively （ns）.  Colonoscopy at the time of 
diagnoses revealed a Matt’s score of 1 in all patients and no specic features predictive of 
proximal extension were noted.
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Proximal extension
　During our investigation period, proximal extension was observed in 14 of 53 patients 
（26%）.  In 7 of these 14 patients, the inflammation did not extend beyond the splenic 
flexure.  Extensive colitis along the ascending colon and the caecum developed in the 
remaining 7 patients.  All cases presented with disease extension within 6 years of the onset 
of ulcerative proctitis.  The cumulative incidence of proximal extension was 4.22/100 person-
years and the cumulative probability at 5 and 10 years was 20.1% and 28.0%, respectively 
（Fig. 1）.
Table 1.  Baseline demography of the patients with and without proximal extension
disease extension （＋）
N=14
disease extension （-）
N=39
P value
male （%） 29 28 NS
age of onset （median, range） 33 （24-55） 33 （18-73） NS
family history 1 （ 7%） 2 （ 5%） NS
active smoking 4 （29%） 3 （ 8%） NS
appendiceal involvement 7 （50%） 14 （39%） NS
corticosteroid requirement 9 （64%） 8 （21%） 0.005
clinical course
   one attack 2 （14%） 14 （36%）
   are-remission 11 （79%） 17 （44%） NS
   chronic active 1 （ 7%） 8 （20%）
aminosalicylates
   mesalamine 8 （57%） 16 （42%） NS
   sufasalazine 6 （43%） 22 （58%）
ns = statistically not
Fig. 1.   Cumulative probability of proximal extension in ulcerative proctitis.
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Association factors
　In univariate analyses, active smoking and corticosteroid therapy were found to be statisti-
cally signicant risk factors （Table 2）.  In a multivariate analysis, corticosteroid therapy was 
still a signicant risk factor with a hazard ratio of 3.813 （95% condence interval, 1.247-
11.659）.
Discussion
　In this investigation, we found that proximal extension developed in 14 of 53 patients 
（26%） with ulcerative proctitis, with a cumulative incidence of 4.22/100 person-years. 
Corticosteroid therapy was found to be significantly associated with proximal extension. 
However, a population-based study may be more useful for generally understanding the 
clinical course of these diseases because such an approach should minimize selection bias. 
Although our study was hospital-based, we made maximum effort to avoid selection bias 
and therefore, our results should represent population-based data.  It is appropriate to men-
tion here that based on the unique health delivery system in Japan, patients are allowed 
to visit any medical institution at their own discretion.  Referrals are not required to visit 
even a tertiary care centre.  Indeed, approximately 40% of the patients in this study were 
not referred by primary care physicians.  Additionally, by the introduction of guidelines, the 
medical therapy of patients with UC has been standardized nationwide.
　Previous studies have reported various rates of disease extension in ulcerative proctitis, 
ranging from 18% to 46% （Table 3）9-15）.  This level of inconsistency may be due to dif-
ferent clinical settings, observation periods, geographical or racial differences, health delivery 
systems, or methods for evaluating the extent of the disease.  However, more recent studies 
consistently show that disease extension in ulcerative proctitis occurs in 18% to 28% of 
cases 2, 12, 13, 15）.  The incidence of proximal extension in this investigation is very similar to 
those in the latter studies, suggesting that the rate of proximal extension in ulcerative procti-
tis may be universal and is not as high as some reports have previously suggested.
Table 2.   Univariate analyses of overall 
risk for proximal extension
P value
male （%） 0.659
age of onset 0.643
family history 0.349
active smoking 0.022
appendiceal involvement 0.379
corticosteroid requirement 0.009
clinical course 0.230
aminosalicylates 0.370
By Log rank test
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　The proximal extension in this study occurred over time.  Langholz et al 10） reported that 
the median interval of extension was 1.3 years, while Moum and colleagues 9） also reported 
that 22% of cases with an initial diagnosis of ulcerative proctitis presented with an increased 
distribution of inammation within a median follow-up time of 14 months, suggesting early 
occurrence of proximal extension.  However, most other studies appear to show a gradual 
increase of the extension and in our investigation, early extension was not prominent.  Pro-
spective studies involving large cohorts of patients may be needed to better understand this 
issue.
　In this study, no patient underwent colectomy during the observation period.  Our nd-
ings are in agreement with the recent report of a very low rate of colectomy in Japanese 
proctitis patients 18）.  These authors found that among 1000 UC patients who required 
surgery, the initial diagnosis of proctitis was only made in 2 cases 18）.  According to previous 
reports from Western countries, the cumulative colectomy rate for UC was 7% to 32% at 
5 years 3, 6, 10）.  However, it should be noted that in more recent reports from Norway and 
Greece, the colectomy rate was very low at zero to 2 %2, 13）.  Development of novel medi-
cations may reect the current decrease in the rate of colectomy.  Interestingly, Stewenius 
et al reported that the period from the onset of symptoms to the diagnosis decreased over 
time 5）, indicating that medical intervention has become faster as well.  Thus, the rate of 
colectomy in proctitis patients may be low and not as high as has been reported even in 
Western countries.
　One explanation for the absence of colectomies in this study might be a better adherence 
to medical care because all patients, except one, were on medical therapy （at least an amin-
osalicylate） during the follow-up period and aminosalicylates have been shown to reduce 
the risk of proximal extension15）.  In contrast, Henriksen et al reported that 65% of UC 
patients with an initial diagnosis of proctitis were free from medication after 5 years of fol-
Table 3.   Previous reports examining the incidence of proximal extension of ulcerative proctitis
observation
 period （months）
Number of patients incidence of extension 
（%）
Western countries 　 　 　
     Langholtz et al 10） 144  61 25
     IBSEN study 2） 60 127 28
     Meucci et al 11） 64 273 27
     Park et al 12） 62.5 134 33 （at 5 years ）
     Moum et al 9） 12 130 22
     Farmer et al 3） 144 516 46
     Chatzicostas et al 13） 132  62 18 （at 5 years）
     Ayres et al 6） 132 145 27 （at 5 years）
Japan
     Hiwatashi et al 14） 106  76 27
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low-up 2）.  Another factor could be the favorable natural course of UC in Asians, compared 
to Westerners 19）.  For example, Probert et al 20） found that migrant South Asian patients 
with UC had a lower risk of colectomy compared to European patients 20）.  A recent study 
in Korea supports this notion, with only 2 of 134 proctitis patients undergoing a colectomy 
within a median follow-up time of 62.5 months 12）.  Different genetic predispositions or 
environmental factors might be responsible for such racial differences.  Interestingly, Pierik et 
al 21） found that Toll-like receptor 1, 2, and 6 polymorphisms inuence disease extension in 
patients with IBD.  Additionally, Western foods are suspected to promote IBD 22）.
　In Japan, studies examining the natural course of ulcerative proctitis are rare.  Hiwatashi 
et al 14） reported the rate of disease extension in ulcerative proctitis patients was 27% 
within a mean follow-up time of 9.6 years and the cumulative probability after 5 years was 
15% to 20%.  The rate of colectomy was very low, at 3.3% or 1 in 55 cases.  The data 
in that study were obtained in a single, but very large hospital.  However, this was over 
20 years ago.  Given the recent availability of new medications and changes in application 
strategies, such as oral and rectal formulations of mesalamine, and rectal formulations of 
prednisolone, together with a dramatic increase in the number of UC patients during the 
past two decades in Japan, it is important to compare changes in the natural course of the 
disease over time.  Surprisingly, with all these new developments, our results detailing proxi-
mal extension in patients with ulcerative proctitis are very similar to those of Hiwatashi’s 
group14）, suggesting that the natural course of ulcerative proctitis has not changed in the 20 
years since these authors published their ndings.
　Several studies have attempted to identify risk factors for proximal extension but the data 
are conicting.  Farmer et al 3） found early disease onset, disease severity, and extra-intestinal 
manifestations to be prognostic factors.  Langholz et al 10） showed that symptomatic mani-
festations such as pain and diarrhea, at the time of diagnosis but not at the time of onset 
of the disease, were associated with proximal extension.  Meucci et al 11） showed that more 
refractory disease requiring corticosteroid therapy, non-smoking, and frequent relapses were 
independent prognostic factors.  Chatzicostas et al 13） also suggested that non-smoking was 
a risk for disease progression, while Pica and colleagues 15） reported that a more prolonged 
oral mesalamine treatment period was protective against proximal spread.  More recently, 
Etchevers et al 23） found that a younger age at diagnosis and the presence of sclerosing 
cholangitis were independent predictive factors for disease extension.
　To identify associated factors, we looked at the clinical and demographic data, taking into 
account the aforementioned reports and our clinical experience.  In a univariate analysis, 
current smoking was associated with disease extension （albeit with a very small sample 
size）.  In general though, cigarette smoking seems to have a protective effect in UC 24）. 
Although positive family history has been reported to be a signicant risk factor in the 
development of UC 12, 25）, we found no association.  Similarly, our nding of no association 
between appendiceal lesions and proximal extension is in line with the report by Byeon 
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and colleagues 26）.  We also compared the effect of mesalamine with sulphasalazine because 
mesalamine is reported to have a protective effect on disease extension 15） and mucosal con-
centrations of total 5-aminosalicylate are much higher in patients taking sulphasalazine than 
mesalamine 27）.  However, it should be noted that this study was not appropriately designed 
to directly compare the efcacy of the aminosalicylates.  Our multivariate analysis showed 
that a requirement for corticosteroid therapy was the only factor associated with disease 
extension, consistent with the reports by Meucci et al and Pica et al 11, 15）.  Patients who 
require corticosteroids may have a more severe or refractory UC and therefore, need more 
frequent check-ups.  Indeed, most of the patients with proximal extension needed more 
aggressive immunosuppressive therapy after proximal extension was diagnosed.
　The limitations of this study should be mentioned.  First, our sample size was small, and 
this might have contributed to low statistical power.  Most of the studies examining the 
natural course of UC include a few hundred cases.  Second, there could be inter-observer 
differences in the diagnosis of ulcerative proctitis.  Baron et al 28） reported difficulties in 
describing mucosal appearance particularly when clearly dened features such as bleeding 
were absent.  However, we think that this can be minimized by reviewing endoscopic photo-
graphs taken at colonoscopy.  Third, as this study was endoscopybased, we could not exclude 
the presence of microscopic inflammation in the proximal site in spite of the diagnosis 
of ulcerative proctitis.  Moum et al 9） reported that the upper extent of inflammation at 
endoscopy did not completely correlate with histological inammation.  Fourth, self-limiting 
proctitis could not be ruled out, which may cause underestimation of the true rate of proxi-
mal extension.  Likewise, colonoscopy was not scheduled which could also underestimate 
the rate.  Nonetheless, this is the most up to date report on the natural course of ulcerative 
proctitis in Japan.
　In conclusion, this investigation found the incidence of proximal extension in ulcerative 
proctitis in Japan to be 26%.  Similarly, the cumulative incidence of proximal extension was 
4.22/100 person-years and the cumulative probability was 20.1% at 5 years.  The colectomy 
rate was zero.  These outcomes are consistent with reports published over two decades ago, 
indicating that the natural course of ulcerative proctitis in Japan has not changed in recent 
years.  Corticosteroid therapy was associated with proximal extension therefore diligent 
follow-up should benet this subgroup.
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